/images/ppid_59c68470-image-1793715034278204.webp)
/images/ppid_59c68470-image-179370004174842952.webp)
/images/ppid_59c68470-image-179362255023716335.webp)
/images/ppid_59c68470-image-179371002860386189.webp)
What is the story about?
Aarti Drugs Ltd
on Tuesday (November 3) reported an 83.2% year-on-year (YoY) increase in net profit to ₹82.9 crore for the second quarter, compared with ₹45.3 crore in the corresponding quarter last year.
Revenue rose 26.6% YoY to ₹826.2 crore from ₹652.8 crore in the year-ago period.
Earnings before interest, tax, depreciation and amortisation (EBITDA) increased 60.6% to ₹135.4 crore from ₹84.3 crore. EBITDA margin expanded to 16.4% from 12.9% in the corresponding quarter last year, an improvement of 350 basis points.
Shares of Aarti Drugs Ltd ended at ₹465.00, up by ₹11.20, or 2.47%, on the BSE.
Revenue rose 26.6% YoY to ₹826.2 crore from ₹652.8 crore in the year-ago period.
Earnings before interest, tax, depreciation and amortisation (EBITDA) increased 60.6% to ₹135.4 crore from ₹84.3 crore. EBITDA margin expanded to 16.4% from 12.9% in the corresponding quarter last year, an improvement of 350 basis points.
Shares of Aarti Drugs Ltd ended at ₹465.00, up by ₹11.20, or 2.47%, on the BSE.
/images/ppid_59c68470-image-179372752132210714.webp)
/images/ppid_59c68470-image-179387502182297278.webp)
/images/ppid_59c68470-image-179389006525882504.webp)
/images/ppid_59c68470-image-179388752861972724.webp)
/images/ppid_59c68470-image-179379002747985612.webp)
/images/ppid_59c68470-image-179364255051298513.webp)
/images/ppid_59c68470-image-179364004384390264.webp)
/images/ppid_59c68470-image-179362752509788758.webp)